Skip to Main Content

Paper Details

Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Leukemia
14
2023
ALL, ATP, ATP-binding cassette transporters, BCL-2, Infants, KMT2A, KMT2A-rearranged B-cell acute, KMT2A-rearranged B-cell acute lymphoblastic leukemia, KMT2A-rearranged acute lymphoblastic leukemia, KMT2A-rearranged infant ALL cell lines, KMT2A-rearranged infant ALL cells, KMT2A-rearranged infant ALL xenografts, azacitidine, decitabine, infant, infants, methotrexate, venetoclax
Author NameAffiliation
Patrick BrownSidney Kimmel Comprehensive Cancer Center, John Hopkins University
Patrick BrownSidney Kimmel Comprehensive Cancer Center, John Hopkins University
Mignon L LohSeattle Children's Hospital
Richard B LockChildren's Cancer Institute, Lowy Cancer Research Centre/School of Women's and Children's Health/UNSW Centre for Childhood Cancer Research
  • 1 - 4

Datasets

Release 1.2